KIMS Q2 Results Review - Operationally Strong Quarter: Prabhudas Lilladher
The company’s robust cost control, low capital intensive set-up, value accretive acquisitions have ensured good profitability.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Krishna Institute of Medical Sciences Ltd. Q2 operating performance was broadly in-line with Ebitda growth of 22% QoQ to Rs 1.6 billion adjusted for one-off expenses (Rs 150 million) and rental.
KIMS’ robust cost control, low capital intensive set-up and value accretive acquisitions have ensured good profitability in past with Ebitda growth of 40% compound annual growth rate over FY18-22.
Also recent acquisitions of Sunshine Hospitals, Nashik and Nagpur are value accretive which will continue to aid growth momentum, in our view.
We expect 17% Ebitda CAGR over FY22-25E with best in class return ratios of 22%/28% return on equity/return on capital employed.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.